Drug Discovery
36 VCs and 3 funds investing in Drug Discovery
VCs investing in Drug Discovery
Tess van Stekelenburg
Partner
Lux Capital
Check: No verified personal or standard Lux check-size range is published. Tess invests at both early and growth stages and participates in Lux company creation; founders should confirm round fit directly rather than infer an allocation from fund size or disclosed company rounds.
Tess is a technically trained generalist investing where AI, biology, aerospace, and the physical world intersect. She seeks engineers and scientists turning frontier research into companies, with particular interest in computational methods that make biology more engineerable, the data and model bottlenecks behind scientific discovery, and high-consequence systems such as biodefense.
Rachelle Young
Investor Relations Director
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Rachelle Young as Investor Relations Director. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Elisa Camorani
Senior Associate ESG and Impact
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Elisa Camorani as Senior Associate ESG and Impact. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Cyril Lesser
Vice President Finance | Funds
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Cyril Lesser as Vice President Finance | Funds. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Arnoud Dijkstra
Venture Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Arnoud Dijkstra as Venture Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Machteld Groeneveld
Chief Compliance Officer & Legal Affairs
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Machteld Groeneveld as Chief Compliance Officer & Legal Affairs. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Oskar Slotboom
Managing Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Oskar Slotboom as Managing Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Daniela Couto
General Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Daniela Couto as General Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Olga Ziessen
Manager Secretarial Services
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Olga Ziessen as Manager Secretarial Services. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Robbert van de Griendt
Head of Investor Relations
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Robbert van de Griendt as Head of Investor Relations. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Wouter Verhoeven
Venture Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Wouter Verhoeven as Venture Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Rianne Ellenbroek
Principal
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Rianne Ellenbroek as Principal. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
John J.P. Kastelein
Senior Advisor
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies John J.P. Kastelein as Senior Advisor. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Patricia Vonk
AML/KYC Manager
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Patricia Vonk as AML/KYC Manager. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Jennifer Fritzsche
Vice President Finance
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Jennifer Fritzsche as Vice President Finance. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Silva Dezelan
Head of Impact and ESG
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Silva Dezelan as Head of Impact and ESG. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Karen Chan
Associate
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Karen Chan as Associate. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Dragana Dragusin
Executive Assistant
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Dragana Dragusin as Executive Assistant. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Elena Ritsou
Venture Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Elena Ritsou as Venture Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Maureen Wouters
Paralegal
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Maureen Wouters as Paralegal. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Rob de Ree
Venture Partner
BioGeneration Ventures
Check: BGV does not publish a standard current startup check-size range on its official site.
The official roster identifies Rob de Ree as Venture Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.
Christina Takke
Managing Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Christina Takke as Managing Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Katja Rosenkranz
Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Katja Rosenkranz as Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Martin Solleveld
Finance Manager
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Martin Solleveld as Finance Manager. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.
Mathias Falcenberg
Venture Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Mathias Falcenberg as Venture Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Shelley Margetson
Managing Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Shelley Margetson as Managing Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Ward Capoen
Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Ward Capoen as Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Willem Broekaert
Managing Partner
V-Bio Ventures
Check: V-Bio does not publish a standard current startup check-size range on its official site.
The official roster identifies Willem Broekaert as Managing Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.
Karel Kubias, MBA
Founding Partner
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Karel Kubias, MBA invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Ivan Vohlmuth
Founding Partner
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Ivan Vohlmuth invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Barbora Šumová, Ph.D.
Partner
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Barbora Šumová, Ph.D. invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Tomáš Maršálek, MBA
Founding Partner
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Tomáš Maršálek, MBA invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Dr. Anela Vukoja
Partner
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Dr. Anela Vukoja invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Magdalena Marciniak, Ph.D.
Advisor
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Magdalena Marciniak, Ph.D. is listed in a Advisor capacity at i&i Bio. The firm does not publish a person-specific investment mandate for this role; the firm's strategy is included only as shared organizational context.
Pavlína Koutecká
Associate
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Pavlína Koutecká invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Simona Šandová
Office Manager
i&i Bio
Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Simona Šandová is listed in a Office Manager capacity at i&i Bio. The firm does not publish a person-specific investment mandate for this role; the firm's strategy is included only as shared organizational context.